Shanghai Pharmaceuticals Holding Co., Ltd (HKG:2607)
11.26
-0.04 (-0.35%)
Apr 3, 2025, 4:08 PM HKT
HKG:2607 Revenue
In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 274.19B CNY with 5.80% growth. Shanghai Pharmaceuticals Holding had revenue of 64.56B in the quarter ending December 31, 2024, with 4.73% growth.
Revenue
274.19B CNY
Revenue Growth
+5.80%
P/S Ratio
n/a
Revenue / Employee
5.55M CNY
Employees
49,402
Market Cap
66.78B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 274.19B | 15.03B | 5.80% |
Dec 31, 2023 | 259.15B | 27.17B | 11.71% |
Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 29.60B |
Hansoh Pharmaceutical Group Company | 13.05B |
WuXi Biologics | 19.87B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Alibaba Health Information Technology | 31.39B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Shanghai Pharmaceuticals Holding News
- 3 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 3 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha